抗人stathmin单克隆抗体及其联合紫杉醇对人乳腺癌细胞的生长抑制作用

中国临床药理学与治疗学 ›› 2010, Vol. 15 ›› Issue (8): 861-865.

抗人stathmin单克隆抗体及其联合紫杉醇对人乳腺癌细胞的生长抑制作用

原少斐¹, 陈文俊¹, 郑维锷¹, 杜红延², 李明², 张武¹, 陈华¹, 吴丽丽¹

¹温州医学院附属第三医院肿瘤中心,温州 325200,浙江;
²南方医科大学生物技术学院,广州 510515,广东

收稿日期:2010-03-11 修回日期:2010-04-24 出版日期:2010-08-26 发布日期:2020-09-17
通讯作者: 陈文俊,男,主任医师,主要从事肿瘤综合治疗。E-mail: cwj2233@126.com
作者简介:原少斐,男, 硕士,医师,主要从事肿瘤内科治疗工作。E-mail: ysf1004@163.com
基金资助:
国家高技术研究发展计划(863)资助项目(2006AA02A311)

Effects of monoclonal antibodies against human stathmin combined paclitaxel on proliferation of human breast carcinoma cell line MCF-7

YUAN Shao-fei¹, CHEN Wen-jun¹, ZHENG Wei-e¹, DU Hong-yan¹, LI Ming², ZHANG Wu¹, CHEN Hua¹, WU Li-li¹

¹Cancer Center, the Third Affiliated Hospital,Wenzhou Medical College, Wenzhou 325000, Zhejiang,China;
²School of Biological Technology, Southern Medical University, Guangzhou 510515, Guangdong, China

Received:2010-03-11 Revised:2010-04-24 Online:2010-08-26 Published:2020-09-17

摘要/Abstract

摘要： 目的: 探讨抗人stathmin单克隆抗体、紫杉醇分别单用或联用对乳腺癌细胞系MCF-7的生长抑制及促凋亡作用。方法: 以不同浓度的抗人stathmin单克隆抗体、紫杉醇分别组成单药组和联合用药组,另设不加药的空白对照组,分别作用于MCF-7细胞24、48、72、96 h,观察细胞数量和形态的变化。MTT法检测单克隆抗体、紫杉醇单用组、联用组以及对照组对MCF-7细胞的增殖抑制作用,用流式细胞仪通过AnnexinV/PI双染法检测各组细胞凋亡率的改变。结果: 不同浓度的各实验组作用后细胞数量明显减少、形态不规则,部分细胞核固缩和胞质减少,而对照组细胞生长状态良好。抗人stathmin单克隆抗体、紫杉醇单用与联用均能抑制MCF-7细胞增殖,呈剂量-时间依赖效应,联用组细胞抑制率较单药组明显增高, 差异具有统计学意义(P<0.05),两药联用有交互效应( P<0.05)。抗人stathmin单克隆抗体、紫杉醇单用与联用均能诱导MCF-7细胞凋亡,联合组更为明显( P<0.05)。结论: 抗人stathmin单克隆抗体、紫杉醇单用与联用均能抑制MCF-7细胞增殖,诱导其凋亡;两药联合作用于人乳腺癌MCF-7细胞具有协同作用。

关键词: stathmin单克隆抗体, 紫杉醇, 乳腺癌, 增殖, 凋亡

Abstract: AIM: To investigate the effects of monoclonal antibodies against stathmin combined paclitaxel on the proliferation of MCF-7 cells.METHODS: MCF-7 cells were treated with monoclonal antibodies against stathmin, paclitaxel alone or their combination, with theuntreated cells used as the control, 24,48,72,96 hours later, the cell growth condition was observed by invert microscope and inhabitation rate was studied by MTT assay ; The apoptosis was analyzed by flow cytometry with Annexin V/PI.RESULTS: The population decreased and shape, size changed after treating with different concentration of experimental groups. Monoclonal antibodies against stathmin and paclitaxel used alone or in combination both inhibited the proliferation of MCF-7 cells,the inhibition ratio of their combination was more higher(P<0.05), and a synergistic effect of the two agents was noted in their combined action (P<0.05). Combined treatment of the cells resulted in significantly higher apoptosis rate than that in the other groups (P<0.05).CONCLUSION: Monoclonal antibodies against stathmin and paclitaxel used alone or in combination both can inhibit proliferation of MCF-7 cells and induce apoptsis. A synergistic effect is observed between the monoclonal antibodies against stathmin and paclitaxel in their inhibition of MCF-7 cell proliferation.

Key words: Monoclonal antibodies against stathmin, Paclitaxel, Breast carcinoma, Proliferation, Apoptosis

中图分类号:

原少斐, 陈文俊, 郑维锷, 杜红延, 李明, 张武, 陈华, 吴丽丽. 抗人stathmin单克隆抗体及其联合紫杉醇对人乳腺癌细胞的生长抑制作用[J]. 中国临床药理学与治疗学, 2010, 15(8): 861-865.

YUAN Shao-fei, CHEN Wen-jun, ZHENG Wei-e, DU Hong-yan, LI Ming, ZHANG Wu, CHEN Hua, WU Li-li. Effects of monoclonal antibodies against human stathmin combined paclitaxel on proliferation of human breast carcinoma cell line MCF-7[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(8): 861-865.

参考文献

[1] 徐兵河. 复发转移乳腺癌的化学治疗[J].中国实用内科杂志,2007,27(3): 24-26.
[2] Burstein H. The distinctive nature of HER2-positive breast cancers[J]. New Engl J Med, 2006, 353(16):1652-1654.
[3] Rubin CI, Atweh GF. The role of stathmin in the regulation of the cell cycle[J]. J Cell Biochem,2004,93(2):242-250.
[4] Jeha S,Luo XN,Beran M,et al.Antisense RNA inhibition of phosphoprotein p18 expression abrogates the transformed phenotype of leukemic cells[J].Cancer Res,2006,56(6):1445-1450.
[5] Zhang HZ,Wang Y,Gao P,et al.Silencing stathmin gene expression by survivin promoter-driven siRNA vector to reverse malignant phenotype of tumor cells[J].Cancer Biol Ther, 2006,5(11): 1457-1641.
[6] Milross CG, Mason KA, Hunter NR, et al. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel[J]. J Natl Cancer Inst, 1996,88(18):1308-1314.
[7] 原少斐,陈筱婷,汪森明,等.抗人微管不稳定蛋白单克隆抗体的制备及鉴定[J].肿瘤防治研究,2009,36(6):18-22.
[8] Cassimers L.The op18/stathmin family of microtubule destabilizers[J].Curr Opin Cell Bio, 2002,14(1):18-24.
[9] Gadea BB,Ruderman JV.Aurora B is required for mitotic chromatininduced phosphorylation of Op18/Stathmin[J]. Proc Natl Acad Sci USA, 2006,103(12):449.
[10] Tuschl T, Borkhardt A. Small interfering RNAs:a revolutionary tool for the analysis of gene function and gene therapy[J]. Mol Interv, 2002,2(3):158-167.
[11] Hainsworth JD,Sosman JA,Spigel DR,et al.Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC) [J]. Pro Am Soc Clin Oncol, 2004,22:382.
[12] 武晓静,葛均波,黄岚,等.紫杉醇对兔血管内皮和平滑肌细胞增生影响的差异及意义[J].中国临床药理学与治疗学, 2006,11(8):902-906.

[1]	何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[2]	张胡云龙, 朱秀之, 金希, 邵志敏. 腔面型乳腺癌内分泌治疗耐药的机制与治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 854-865.
[3]	付晓玉, 孔德光, 李娟娟. 三阳性乳腺癌的治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 866-875.
[4]	罗师萍, 张捷, 俞育帅, 宋传贵. HER2阳性乳腺癌的靶向治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 876-886.
[5]	向奕玫, 张宁宁, 黄雨昕, 曾晓华. HER2阳性乳腺癌疗效相关生物标志物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 887-897.
[6]	陈柯羽, 黄圆, 王晓稼, 郑亚兵. 抗体偶联药物在乳腺癌中的临床应用与研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 898-909.
[7]	李梦茜, 张克兢, 夏凡. 乳腺癌疫苗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 918-925.
[8]	范杰, 金永明, 江孝龙, 蒋国华. lncRNA HOTAIR调控miR-206影响类风湿关节炎滑膜细胞增殖和凋亡的分子机制研究[J]. 中国临床药理学与治疗学, 2023, 28(7): 736-742.
[9]	王安婧, 王亚亚, 梁轩, 闫雅婕, 苏静, 李彩东. 基于PPAR治疗胆汁淤积性肝病的机制与药物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 796-808.
[10]	杨晓佳, 江萌, 吴敏, 张伊黎, 吕兰, 吴嫄芬, 王鑫昱, 刘立权. 藏红花素介导DKK3调控GSK-3β/β-catenin通路对阿尔兹海默症大鼠的认知改善作用[J]. 中国临床药理学与治疗学, 2023, 28(5): 489-497.
[11]	王艳, 张金辉, 赵永辰, 刘宏祥, 刘亚维, 苗欢欢, 杨信才. 红杉黄酮通过下调PI3K/AKT信号通路抑制胃癌细胞增殖侵袭等干细胞特性[J]. 中国临床药理学与治疗学, 2023, 28(5): 508-513.
[12]	侯小煜, 冷玉芳, 曹雪芬, 吕兴娇, 韩晓霞, Janvier NIBARUTA, 刘永强. 五味子乙素减轻小鼠肠缺血再灌注损伤的网络药理学分析及实验验证[J]. 中国临床药理学与治疗学, 2023, 28(2): 147-154.
[13]	王智, 周鑫, 何雪茹, 付裕豪, 荀雪姣, 李颖, 董占军. 哌柏西利治疗乳腺癌的临床研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 205-213.
[14]	王剑, 孙永东, 周兴玮, 刘雷, 陈龙, 童兴科, 朱佳丽. 黄芩素经由miR-125b-5p/IRF4轴进而促进喉癌细胞死亡并抑制其侵袭的机制研究[J]. 中国临床药理学与治疗学, 2023, 28(11): 1209-1218.
[15]	朱瑞芳, 郭东凯, 智慧, 江翊国, 张悦翎, 钱晓萍, 季士亮. ROS-NF-κB-p38MAPK通路探索榄香烯联合硼替佐米抗多发性骨髓瘤的机制研究[J]. 中国临床药理学与治疗学, 2023, 28(11): 1219-1226.